



Drug Utilization Review Board Meeting Minutes In-Person and Virtual Meeting Format January 11, 2022

The Nebraska Drug Utilization Review (DUR) Board met January 11, 2022. A hybrid format of in-person and virtual via Webex was held. It originated at the Country Inn Suites in Lincoln, Nebraska.

DUR Board Members in attendance in-person or via Webex -- Phil Vuchetich, RP; Robert Wergin, MD., Anthony Ross, M.D., Tim Bourke, RP., Tom Dunn, R.P., Bruce Houghton, M.D., David Randolph, RP., Charlie Moore, R.P.

DUR Board Member not in attendance: Susan Howard, MD.

DHHS attendees: Leah Spencer, R.N., Program Specialist; Dianne Garside, R.P., Spencer Moore, R.P., Ken Saunders, R.P., Director of Pharmacy for Nebraska Medicaid

Contracted attendees: Nikia Bennette-Carter, RP, Magellan Rx Management; Elanah Figueroa, Magellan RX Management; Jamie Benson, RP, Nebraska Total Care; Shannon Nelson, RP, Nebraska HealthyBlue; Bernadette Ueda, RP, United Health Care.

Public visitors attended via Webex and in-person.

I. Call to Order

The meeting was called to order by Ken Saunders on January 11, 2022 at 6:35 pm CST. Members and attendees were welcomed and asked to introduce themselves. Public attendees were directed to complete a sign-in sheet to be added to the meeting minutes. Ken Saunders made known that meeting materials and the Open-Meetings Law were available. The Board welcomed Tom Dunn, R.P. He was added to the DUR Board and is taking over Kevin Borchers' place as pharmacist.

II. Conflict of Interest

Saunders called for declaration of conflicts of interest. None were declared.

III. Agenda approval

No changes were made to the January 11, 2022 meeting agenda as presented. A motion was made by Anthony Ross and seconded by Robert Wergin to approve the agenda. The motion was voted upon and approved.

IV. Meeting Minutes from November 9, 2021

The Minutes were reviewed from the November 9, 2021 DUR Board meeting and voted upon by the members. The DRAFT minutes were passed as written. It passed with Houghton and Wergin both abstaining due to their absence from the November 9, 2021 meeting.

V. Special Topics

The MME results from the Annual CMS Survey were reviewed by Saunders. A discussion was had that included how far Nebraska has come in respect to tapering down to 90 MME. The discussion included the multiple MME values for the states and how some states were represented by multiple MCO's and how some of the states had multiple MME values compared to other states.

National MME Limits (2020 MCO vs. FFS)

Response	States (Count of MCOs)	Total	% of Total	Response	States (FFS)	Count	% of Total
100 MME	Massachusetts (1), New Hampshire (3)	4	1.72%	100 MME	New Hampshire	1	2.08%
120 MME	California (3), Hawaii (3), Michigan (7), New Jersey (3), Utah (1), Washington (5)	22	9.48%	120 MME	Hawaii, Massachusetts, Michigan, New Jersey, Washington, Wyoming	6	12.50%
200 MME	California (8), Colorado (1), Illinois (2), Kentucky (1), Maryland (1), Michigan (2), New York (6), North Dakota (1), Oregon (1)	23	9.91%	200 MME	Alabama, Alaska, Colorado, Kentucky, Missouri, Tennessee	6	12.50%
50 MME	California (1), Georgia (1), Indiana (3), Kentucky (1), Pennsylvania (7)	13	5.60%	50 MME	Indiana, Nevada, Pennsylvania, Vermont, West Virginia	5	10.42%
80 MME	Kentucky (1), Ohio (3)	4	1.72%	80 MME	Georgia	1	2.08%
90 MME	Arkansas (3), California (11), Delaware (2), District of Columbia (4), Florida (15), Georgia (3), Hawaii (3), Illinois (5), Indiana (1), Iowa (2), Kansas (3), Kentucky (2), Louisiana (5), Maryland (8), Massachusetts (3), Michigan (2), Minnesota (8), Mississippi (3), Nebraska (3), Nevada (3), New Jersey (2), New Mexico (3), New York (11), Ohio (1), Oregon (19), Rhode Island (3), South Carolina (5), Texas (17), Utah (3), Virginia (6)	159	68.53%	90 MME	Arkansas, Connecticut, Delaware, District of Columbia, Florida, Idaho, Illinois, Iowa, Kansas, Louisiana, Maryland, Minnesota, Mississippi, Montana, Nebraska, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, South Carolina, South Dakota, Texas, Utah, Virginia	26	54.17%
> 200 MME	California (2), Colorado (1), Florida (1)	4	1.72%	> 200 MME	California	1	2.08%
< 50 MME	Massachusetts (1), Ohio (1), Pennsylvania (1)	3	1.29%	< 50 MME	Maine, Ohio	2	4.17%
National Totals		218	100%	National Totals		48	100%

It was discussed by the DUR Board that the semi-annual SUPPORT Act data will be reviewed by the DHHS and the DUR Board members during the next meeting on March 8, 2022. Saunders related that this would include the use benzodiazepines, opioids, antipsychotics, and gabapentin-type medications. Antipsychotic use in children continues to be an important category for review in the SUPPORT Act. DHHS will prepare the data from the categories to be reviewed and send out to the DUR Board members prior to the meeting.

VI. Future Meeting Date

The next DUR Board Meeting is scheduled for Tuesday March 8, 2022 at the Country Inn Suites. The dinner session for the DUR Board members will start promptly at 6:00 PM CST, with the public session to begin at 6:30 PM CST.

VII. Concerns & Comments

There were no topics discussed or shared by the DUR Board members, the public members or DHHS personnel. Saunders reminded the DUR Board members that the March meeting will include the review of the six month SUPPORT Act data. Saunders reminded the DUR Board members that the data will be shared with them before the meeting. Please review before the meeting in March.

VIII. Adjournment

A motion was made by the DUR Board members and passed with a vote of 100% in the affirmative. Meeting adjournment was at 7:20 PM.